Heartflow (NASDAQ:HTFL) CFO Sells $1,368,462.60 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 27,540 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60. Following the completion of the sale, the chief financial officer owned 221,143 shares of the company’s stock, valued at approximately $10,988,595.67. The trade was a 11.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The shares were sold at an average price of $50.60, for a total value of $297,325.60.

Heartflow Price Performance

Shares of HTFL stock traded down $0.80 on Friday, hitting $48.91. The company’s stock had a trading volume of 1,406,810 shares, compared to its average volume of 1,541,654. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.78. The firm’s fifty day moving average price is $33.50 and its 200-day moving average price is $29.79. The stock has a market capitalization of $4.25 billion and a price-to-earnings ratio of -26.73.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business had revenue of $64.08 million during the quarter. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Analysts predict that Heartflow, Inc. will post -0.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Heartflow

A number of large investors have recently added to or reduced their stakes in the business. TrueMark Investments LLC grew its position in shares of Heartflow by 1.4% in the first quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock valued at $654,000 after purchasing an additional 379 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow in the fourth quarter valued at $27,000. Strs Ohio boosted its holdings in Heartflow by 35.3% in the first quarter. Strs Ohio now owns 4,600 shares of the company’s stock valued at $112,000 after acquiring an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Heartflow in the fourth quarter valued at $45,000. Finally, Legal & General Group Plc acquired a new position in Heartflow in the third quarter valued at approximately $59,000.

Wall Street Analyst Weigh In

HTFL has been the subject of several analyst reports. Stifel Nicolaus raised their target price on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Benchmark reissued a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Freedom Capital upgraded Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Morgan Stanley boosted their price target on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Finally, JPMorgan Chase & Co. boosted their target price on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Heartflow currently has an average rating of “Moderate Buy” and a consensus price target of $43.43.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.